Business · 08/03/2019Updated: 10/17/2026 · 1 min read
FDA Announces Draft Guidance on Nonproprietary Naming of Biological Products
Summary
The Food and Drug Administration (FDA) has released a draft guidance for industry on nonproprietary naming of biological products, which updates its previous guidance and considers revising its naming convention for vaccines and transition biological products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →